Patents Assigned to HAEMOSTATIX LIMITED
-
Patent number: 11246958Abstract: A sterile, ready-to-use, flowable haemostatic composition comprises a soluble haemostatic agent comprising a plurality of carriers and a plurality of fibrinogen binding peptides immobilised to the carrier; a biocompatible liquid; and particles of biocompatible cross-linked polysaccharide suitable for use in haemostasis and which are insoluble in the biocompatible liquid. Such compositions may be used for the control of bleeding, especially in surgical procedures.Type: GrantFiled: May 11, 2016Date of Patent: February 15, 2022Assignee: HAEMOSTATIX LIMITEDInventors: Renata Zbozien, John Benjamin Nichols
-
Patent number: 10994047Abstract: Peptide dendrimers and agents are described, which can be used for polymerising fibrinogen and as haemostatic agents. The peptide dendrimers comprise a branched core, and a plurality of fibrinogen-binding peptides separately covalently attached to the branched core.Type: GrantFiled: January 8, 2015Date of Patent: May 4, 2021Assignee: HAEMOSTATIX LIMITEDInventor: Renata Zbozien
-
Patent number: 9913876Abstract: A biogel, and kits, agents, and methods for formation of the biogel are described. The biogel can be used for a variety of applications, including haemostasis, wound sealing, tissue engineering or localized drug delivery.Type: GrantFiled: April 13, 2016Date of Patent: March 13, 2018Assignee: Haemostatix LimitedInventor: Greg Walker
-
Patent number: 9808553Abstract: Haemostatic wound dressings are described. The dressings comprise a non-colloidal porous dressing material, and a plurality of fibrinogen-binding peptides immobilised to the non-colloidal porous dressing material, wherein each fibrinogen-binding peptide comprises: an amino acid sequence Gly-Pro-Arg-Xaa (SEQ ID NO: 1) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Val, preferably Pro, Sar, or Leu; or an amino acid sequence Gly-His-Arg-Xaa (SEQ ID NO: 2) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Pro. The dressings are able to accelerate haemostasis without requiring enzymatic activity. In particular, the dressings to do not rely on the action of exogenous thrombin, and can be stored long-term at room temperature in solution. Methods of making the dressings, and use of the dressings to control bleeding are also described.Type: GrantFiled: February 1, 2013Date of Patent: November 7, 2017Assignee: HAEMOSTATIX LIMITEDInventors: Greg Walker, Sarah Margaret Middleton
-
Patent number: 9724379Abstract: Therapeutic agents with improved fibrinogen binding properties are described. The agents are suitable for use as artificial platelets, or for formation of biogels. Methods and intermediates for producing the agents, cross-linking agents for use in the methods, and biogels formed from, or comprising the agents, are also described.Type: GrantFiled: February 1, 2012Date of Patent: August 8, 2017Assignee: Haemostatix LimitedInventor: Greg Walker
-
Patent number: 9339584Abstract: A biogel, and kits, agents, and methods for formation of the biogel are described. The biogel can be used for a variety of applications, including haemostasis, wound sealing, tissue engineering or localized drug delivery.Type: GrantFiled: November 27, 2007Date of Patent: May 17, 2016Assignee: Haemostatix LimitedInventor: Greg Walker
-
Publication number: 20150071985Abstract: Haemostatic wound dressings are described. The dressings comprise a non-colloidal porous dressing material, and a plurality of fibrinogen-binding peptides immobilised to the non-colloidal porous dressing material, wherein each fibrinogen-binding peptide comprises: an amino acid sequence Gly-Pro-Arg-Xaa (SEQ ID NO: 1) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Val, preferably Pro, Sar, or Leu; or an amino acid sequence Gly-His-Arg-Xaa (SEQ ID NO: 2) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Pro. The dressings are able to accelerate haemostasis without requiring enzymatic activity. In particular, the dressings to do not rely on the action of exogenous thrombin, and can be stored long-term at room temperature in solution. Methods of making the dressings, and use of the dressings to control bleeding are also described.Type: ApplicationFiled: February 1, 2013Publication date: March 12, 2015Applicant: HAEMOSTATIX LIMITEDInventors: Greg Walker, Sarah Margaret Middleton
-
Publication number: 20140031293Abstract: Therapeutic agents with improved fibrinogen binding properties are described. The agents are suitable for use as artificial platelets, or for formation of biogels. Methods and intermediates for producing the agents, cross-linking agents for use in the methods, and biogels formed from, or comprising the agents, are also described.Type: ApplicationFiled: February 1, 2012Publication date: January 30, 2014Applicant: HAEMOSTATIX LIMITEDInventor: Greg Walker